BRAF and non-small cell lung carcinoma: The integration of MEKis with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors, and B-Raf inhibitors to enhance clinical efficacy in NSCLC has been investigated (43).